CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
NCT02752243 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2022-04-01
Summary
Multi-site, non-randomized Phase I/II study involving children and adults.
Conditions
Interventions
- DRUG
-
CIK-Cells
IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
Sponsors & Collaborators
-
Peter Bader
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 0 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2023-03-31
- Completion
- 2024-03-31
Countries
- Germany
Study Locations
More Related Trials
-
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
NCT07256210 ·Status: RECRUITING ·Phase: PHASE2
-
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT01423747 ·Status: UNKNOWN ·Phase: PHASE3
-
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
NCT01904136 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
NCT01423500 ·Status: UNKNOWN ·Phase: PHASE3
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
NCT05796570 ·Status: RECRUITING ·Phase: PHASE2
-
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
NCT02458235 ·Status: COMPLETED ·Phase: PHASE2
-
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
NCT04893915 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase I Extension Trial of Repeated Infusions of ISF35
NCT00783588 ·Status: COMPLETED ·Phase: PHASE1
-
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
NCT04628338 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
NCT00002832 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome
NCT00016419 ·Status: COMPLETED ·Phase: PHASE2
-
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
NCT01772953 ·Status: COMPLETED ·Phase: PHASE2
-
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
NCT00047268 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
NCT01287104 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
NCT00116467 ·Status: COMPLETED ·Phase: PHASE2
-
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia
NCT00001144 ·Status: COMPLETED ·Phase: PHASE2
-
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
NCT07254793 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
NCT01392989 ·Status: COMPLETED ·Phase: PHASE2
-
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
NCT00185757 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell
NCT00447460 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
NCT00569179 ·Status: TERMINATED ·Phase: PHASE1
-
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
NCT00005946 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
NCT00520468 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
NCT03773393 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
NCT01518153 ·Status: TERMINATED ·Phase: PHASE2